CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Grant or award President and CEO acquired 317,800 shares (grant or award)
- 8-K Event Material agreement
- SC 13G/A Stake Amended Statement of Ownership
- 4 Shares withheld for taxes EVP of R&D gave up 24,690 shares (to pay taxes)
- SC 13G/A Stake Amended Statement of Ownership
- 144 Insider Sale of Securities
- 8-K Event Material agreement · Exit or restructuring costs · Other events
- UPLOAD Other SEC-generated Letter
- 4 Planned sale Director sold 18,640 shares at $2.70 ($50,317)
- 8-K Event Other events
- 144 Insider Sale of Securities
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- 424B5 Offering Prospectus
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- SC 13D/A Stake Beneficial Ownership Report
- 4 Grant or award CHIEF FINANCIAL OFFICER acquired 790,000 shares (grant or award)
- 8-K/A Event Executive or director change
- 3 Insider Initial Statement of Ownership
Page 12 of 30 · 587 filings